TURKU, FI / ACCESS Newswire / December 8, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Significant efficacy observed in TP53-mutated patients with a 70% complete remission rate in the ...

Median overall survival (mOS) with bexmarilimab and azacitidine in relapsed/refractory (r/r) HR-MDS patients reached 14.5 months (increased from 13.4 months observed earlier), a significant ...

Next year is bringing many changes to the regulatory landscape for skilled nursing. With new payment rules, coding changes ...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, ...

“For many years, the standard of care for ASHL was based on the RATHL trial, where newly diagnosed patients were given two cycles of ABVD [doxorubicin, bleomycin, vinblastine, and dacarbazine] and ...

Market forecasters project the CAR-T cell therapy market will surge from $3.87 billion in 2024 to $13.25 billion by 2030, driven by unprecedented efficacy in relapsed and refractory patient ...

Beyond blood cancers, GT Biopharma is developing GTB-5550, which targets B7H3, a protein commonly found across various solid tumor types including breast, lung, ovarian, pancreatic, bladder, and ...

Myelodysplastic syndromes (MDS) are a group of related conditions that interfere with the body’s ability to make healthy blood cells. They are a type of blood cancer. In the early stages of ...

FRONTLINE Editor-in-Chief and Executive Producer Raney Aronson-Rath sits down with journalists and filmmakers for probing conversations about the investigative journalism that drives each FRONTLINE ...

TURKU, FINLAND / ACCESS Newswire / December 17, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)(AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers ...